echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Br J Cancer: LIMCH1 and HLA-DQB1 are potential markers of invasive cervical cancer

    Br J Cancer: LIMCH1 and HLA-DQB1 are potential markers of invasive cervical cancer

    • Last Update: 2021-03-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Cervical cancer is the fourth most common type of cancer among women in the world, and it kills more than 311,000 patients every year.
    Most cancer-related deaths are related to tumor metastasis or disease recurrence after primary treatment of the disease.

    In cervical cancer, 90% of the disease recurrence occurs within 3 years of initial diagnosis , and less than 5% of patients survive for more than 5 years.
    Due to the extremely poor prognosis of advanced cervical cancer, there are few treatment options.
    Therefore, the identification of effective molecular markers is essential to improve the personalized treatment of patients.

    Diagnosis and identification of effective molecular markers is essential to improve the personalized treatment of patients.
    The identification of effective molecular markers is essential to improve the personalized treatment of patients.

    The study aims to investigate the cervical cancer transcription data related to patient survival and recurrence to identify potential aggressive disease drivers.


    The researchers compared the RNA sequencing data of the primary tumors of 20 relapsed patients and 53 cured patients, and used immunohistochemistry to determine the protein levels and prognostic effects of selected markers.


    immunity

    Identification of prognostic characteristics

    The results showed that based on the patient's disease recurrence status, the researchers found 121 differentially expressed genes, from which 10 markers with high prognostic significance were identified and verified in an independent patient cohort.


    After adjusting the established prognostic indicators, the researchers found that the protein levels of the two marker genes, HLA-DQB1 and LIMCH1, are independent predictors of patient survival (HLA-DQB1 has a hazard ratio of 2.
    50 and LIMCH1 is 3.


    19) .



    The prognostic impact of 10 genetic markers

    All in all, the results of this study revealed 10 genetic markers with high prognostic ability in cervical cancer.
    Among them, HLA-DQB1 and LIMCH1 may become potential biomarkers for guiding the treatment of cervical cancer.

    The results of this study revealed 10 genetic markers with high prognostic ability in cervical cancer.
    Among them, HLA-DQB1 and LIMCH1 may become potential biomarkers for guiding the treatment of cervical cancer.
    The results of this study revealed 10 genetic markers with high prognostic ability in cervical cancer.
    Among them, HLA-DQB1 and LIMCH1 may become potential biomarkers to guide the treatment of cervical cancer.


    Original source:


    Halle, MK, S?dal, M.
    , Forsse, D.
    et al.


    org/10.
    1038/s41416-021-01305-0">A 10-gene prognostic signature points to LIMCH1 and HLA-DQB1 as important players in aggressive cervical cancer disease .


    org/10.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.